StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
353810.KQ$6040.00-4.13%
Fair $6040.00+0.0%

353810.KQ

EASY BIO,Inc.

Unknown / UnknownKOSDAQ

$6040.00

-260.00 (-4.13%)

Fairly Valued+0.0%Fair Value $6040.00Fund rank 27/100 · Data gapFallback financials|
SA 52/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 27% · confianza 25%

FCF escenarios

weak_data · normalized FCF $28.4B · quality 36.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 37/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 353810.KQLocal privado en este navegador · EASY BIO,Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$199.8B

P/E

7.2x

↓

EV/EBITDA

5.4x

↓

ROE

25.9%

↑

Gross Margin

25.4%

↓

Debt/Equity

1.43

↑
52-Week Range$6040
$4885$8560

TradingView lightweight chart

353810.KQ price, volumen y niveles de valoración

Último $6,040Periodo +496.1%
Fair value: $6,040

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+45.3%

FCF CAGR

—

FCF margin

5.9%

FCF / Net income

1.02x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $476.94B · net income $27.78B · FCF $28.35B

2022-FY → 2025-FY

Gross margin

25.4%-5.0% pts

Operating margin

9.4%-1.0% pts

Net margin

5.8%-0.0% pts

FCF margin

5.9%+12.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$476.94B$476.94B$384.33B$165.39B$155.56B
Net Income$27.78B$27.78B$19.60B$15.54B$9.13B
EBITDA$54.52B$54.52B$42.91B$26.98B$17.47B
EPS840.00840.00579.00455.00267.00
Gross Margin25.4%25.4%25.6%31.5%30.4%
Operating Margin9.4%9.4%8.4%12.5%10.4%
Net Margin5.8%5.8%5.1%9.4%5.9%
Balance Sheet
Debt/Equity1.431.432.501.311.65
Cash Flow
Free Cash Flow$28.35B$28.35B$21.48B$31.72B$-10.17B
Returns
ROE25.9%25.9%23.3%24.8%18.3%
Valuation
P/E7.197.197.407.8615.17
EV/EBITDA5.365.366.876.5010.35
P/B1.861.861.731.952.77
Growth & Yield
Revenue Growth24.1%24.1%132.4%6.3%—
EPS Growth45.1%45.1%27.3%70.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-13.9%

fácil

EPS terminal req.

$535.95

Spread vs growth

59.0%

5Y implied EPS CAGR

-5.0%

fácil

EPS terminal req.

$648.50

Spread vs growth

50.1%

10Y implied EPS CAGR

2.2%

fácil

EPS terminal req.

$1044.41

Spread vs growth

42.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +9.6%

Total return

+9.6%

Start / end P/E

9.5x → 7.2x

EPS bridge

579.00 → 840.00

Residual

-11.0%

EPS growth+45.1%
Multiple rerating-24.4%
Dividend+0.0%
Residual / FX / buybacks / cross-term-11.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.